R
Robert L. Reid
Researcher at Queen's University
Publications - 211
Citations - 8496
Robert L. Reid is an academic researcher from Queen's University. The author has contributed to research in topics: Hormonal contraception & Menstrual cycle. The author has an hindex of 43, co-authored 199 publications receiving 7861 citations. Previous affiliations of Robert L. Reid include Health Canada & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
The Premenstrual Syndrome
Robert L. Reid,Samuel S. C. Yen +1 more
TL;DR: The reversible "medical ovariectomy" attained with this agonist suggests that it may be an effective and rational treatment for this distressing syndrome in the short term.
Journal ArticleDOI
The 2017 hormone therapy position statement of The North American Menopause Society.
JoAnn V. Pinkerton,Fernando Sánchez Aguirre,Jennifer Blake,Felicia Cosman,Howard N. Hodis,Susan Hoffstetter,Andrew M. Kaunitz,Sheryl A. Kingsberg,Pauline M. Maki,JoAnn E. Manson,Polly Marchbanks,Michael R. McClung,Lila E. Nachtigall,Lawrence M. Nelson,Diane Todd Pace,Robert L. Reid,Phillip M. Sarrel,Jan L. Shifren,Cynthia A. Stuenkel,Wulf H. Utian +19 more
TL;DR: Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture.
Journal ArticleDOI
Fluoxetine in the Treatment of Premenstrual Dysphoria
Meir Steiner,Susanne Steinberg,Donna E. Stewart,Diana Carter,Charlene Berger,Robert L. Reid,Douglas Grover,David L. Streiner +7 more
TL;DR: This study evaluated the efficacy and safety of fluoxetine (which selectively inhibits the reuptake of serotonin) in the treatment of premenstrual dysphoria and found it to be safe and effective.
Journal ArticleDOI
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.
Wulf H. Utian,David F. Archer,Gloria Bachmann,Gallagher C,Grodstein Fn,Heiman,Victor W. Henderson,Howard N. Hodis,Richard H. Karas,Roger A. Lobo,JoAnn E. Manson,Robert L. Reid,Peter Schmidt,Cynthia A. Stuenkel +13 more
TL;DR: Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered, and a recommended list of areas for future HT research.
Journal ArticleDOI
A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women.
TL;DR: Transient inhibition of aromatases activity in the early follicular phase with the aromatase inhibitor letrozole results in stimulation of ovarian folliculogenesis similar to that seen with clomiphene citrate with no apparent adverse effect on endometrial thickness or pattern at midcycle.